Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog

PAR4 (Protease-Activated Receptor 4)

(2018) Xu Han et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet TherapeuticsHighlights

(2018) Benjamin E. Tourdot et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

(2018) Gamariel Rwibasira Rudinga et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Current and future antiplatelet therapies: emphasis on preserving haemostasis

(2018) James D. McFadyen et al.   Nature Reviews Cardiology

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis

(2017) Carlo Patrono et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4

(2017) HongBin Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

(2017) Pancras C. Wong et al.   Science Translational Medicine

Targeting PAR1: Now What?

(2017) Robert Flaumenhaft et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Recent innovations in the structural analysis of heparin

(2016) Edwin A. Yates et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Old and new applications of non-anticoagulant heparin

(2016) Giuseppe Cassinelli et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist

(2015) Brian E. Hawes et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CLL2-1, a chemical derivative of orchid 1,4-phenanthrenequinones, inhibits human platelet aggregation through thiol modification of calcium-diacylglycerol guanine nucleotide exchange factor-I (CalDAG-GEFI)

(2015) Chieh-Yu Liao et al.   FREE RADICAL BIOLOGY AND MEDICINE

Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?

(2014) Kurt Huber et al.   AMERICAN HEART JOURNAL

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race

(2014) L. C. Edelstein et al.   BLOOD

Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis

(2014) M. M. Mumaw et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Novel antiplatelet agents in acute coronary syndrome

(2014) Francesco Franchi et al.   Nature Reviews Cardiology

Thrombin-induced platelet activation via PAR4: pivotal role for exosite II

(2014) Niklas Boknäs et al.   THROMBOSIS AND HAEMOSTASIS

The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation

(2010) Chin-Chung Wu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Heparin/heparan sulphate-based drugs

(2010) Neha S. Gandhi et al.   DRUG DISCOVERY TODAY

Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood

(2010) G. L. MENDOLICCHIO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets

(2010) C.-C. Wu et al.   THROMBOSIS AND HAEMOSTASIS

Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib

(2010) Alessandro Zarpellon et al.   THROMBOSIS AND HAEMOSTASIS

The anti-inflammatory effects of heparin and related compounds

(2007) Edward Young   THROMBOSIS RESEARCH